[
  {
    "ts": null,
    "headline": "AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE",
    "summary": "Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025. Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
    "url": "https://finnhub.io/api/news?id=46419f17bf48759a232679950f59261b507eec568672e8e5ec4375709d2e95c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756497660,
      "headline": "AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE",
      "id": 136575401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025. Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
      "url": "https://finnhub.io/api/news?id=46419f17bf48759a232679950f59261b507eec568672e8e5ec4375709d2e95c6"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shared insight on. A caller inquired about the company, noting its recent approval for a memory loss treatment. Cramer replied: “Okay, the memory loss is not that important… because it’s just a very hard thing. I mean, actually, if you want memory […]",
    "url": "https://finnhub.io/api/news?id=8996602a6da8d5d17214f8591fecc2e08417f4da0706b9a5dd7547d11db82a8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756494330,
      "headline": "Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill",
      "id": 136575312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shared insight on. A caller inquired about the company, noting its recent approval for a memory loss treatment. Cramer replied: “Okay, the memory loss is not that important… because it’s just a very hard thing. I mean, actually, if you want memory […]",
      "url": "https://finnhub.io/api/news?id=8996602a6da8d5d17214f8591fecc2e08417f4da0706b9a5dd7547d11db82a8c"
    }
  },
  {
    "ts": null,
    "headline": "Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase",
    "summary": "Royalty Pharma plc (NASDAQ:RPRX) is one of the most undervalued and overlooked large-cap stocks. On August 25, Royalty Pharma plc (NASDAQ:RPRX) said it bought royalty rights to Amgen’s cancer drug ‘Imdeltra’ from BeOne Medicines for $885 million. Imdeltra is a treatment that works by directing the body’s immune T-cells to attack cancer cells through a target […]",
    "url": "https://finnhub.io/api/news?id=7445c18ad95d403f2dee621b3149525a4debde87574347dac8e6138e46dfea09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756493840,
      "headline": "Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase",
      "id": 136575403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Royalty Pharma plc (NASDAQ:RPRX) is one of the most undervalued and overlooked large-cap stocks. On August 25, Royalty Pharma plc (NASDAQ:RPRX) said it bought royalty rights to Amgen’s cancer drug ‘Imdeltra’ from BeOne Medicines for $885 million. Imdeltra is a treatment that works by directing the body’s immune T-cells to attack cancer cells through a target […]",
      "url": "https://finnhub.io/api/news?id=7445c18ad95d403f2dee621b3149525a4debde87574347dac8e6138e46dfea09"
    }
  },
  {
    "ts": null,
    "headline": "Amgen partners with Veeva Systems to enhance clinical trial processes",
    "summary": "Veeva Systems will provide Amgen with a connected platform that spans various data applications and clinical operations.",
    "url": "https://finnhub.io/api/news?id=3a1f04d9939614a2df9dc4b2e7eac4966cf9ee41809f8f5f687ec638c856939b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756460423,
      "headline": "Amgen partners with Veeva Systems to enhance clinical trial processes",
      "id": 136569346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Veeva Systems will provide Amgen with a connected platform that spans various data applications and clinical operations.",
      "url": "https://finnhub.io/api/news?id=3a1f04d9939614a2df9dc4b2e7eac4966cf9ee41809f8f5f687ec638c856939b"
    }
  }
]